Profile data is unavailable for this security.
About the company
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
- Revenue in USD (TTM)0.00
- Net income in USD-41.63m
- Incorporated2007
- Employees32.00
- LocationRegulus Therapeutics Inc4224 Campus Point Court, Suite 210SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 202-6300
- Fax+1 (302) 655-5049
- Websitehttps://www.regulusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 86.67m | 68.00 | -- | -- | -- | 224.53 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Monopar Therapeutics Inc | 0.00 | -6.47m | 87.93m | 10.00 | -- | 11.87 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 89.73m | 235.00 | -- | -- | 18.48 | 0.2948 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -51.47m | 90.56m | 63.00 | -- | 0.4576 | -- | -- | -0.9998 | -0.9998 | 0.00 | 3.82 | 0.00 | -- | -- | 0.00 | -21.24 | -21.16 | -22.36 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Regulus Therapeutics Inc | 0.00 | -41.63m | 92.36m | 32.00 | -- | 1.06 | -- | -- | -1.08 | -1.08 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -63.31 | -53.74 | -71.29 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 93.52m | 15.00 | 4.64 | 0.5323 | 4.46 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Chimerix Inc | 159.00k | -83.59m | 93.53m | 72.00 | -- | 0.6889 | -- | 588.26 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Cidara Therapeutics Inc | 18.86m | -123.53m | 94.07m | 69.00 | -- | 0.8136 | -- | 4.99 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Ikena Oncology Inc | 659.00k | -59.60m | 95.60m | 18.00 | -- | 0.6292 | -- | 145.06 | -1.24 | -1.24 | 0.0137 | 2.78 | 0.0036 | -- | -- | 15,325.58 | -32.72 | -29.72 | -35.50 | -34.62 | -- | -- | -9,043.85 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Werewolf Therapeutics Inc | 3.39m | -62.12m | 96.14m | 45.00 | -- | 1.08 | -- | 28.39 | -1.50 | -1.50 | 0.0819 | 2.04 | 0.0214 | -- | 1.06 | 72,042.55 | -39.26 | -- | -42.91 | -- | -- | -- | -1,834.55 | -- | -- | -- | 0.2228 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 96.26m | -- | 5.58 | 0.1948 | 49.78 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Ovid Therapeutics Inc | 567.53k | -29.75m | 96.52m | 40.00 | -- | 1.09 | -- | 170.07 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| MDxHealth SA | 80.74m | -40.80m | 98.00m | 300.00 | -- | -- | -- | 1.21 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Relmada Therapeutics Inc | 0.00 | -86.49m | 98.07m | 20.00 | -- | 2.06 | -- | -- | -2.87 | -2.87 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -104.91 | -- | -116.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Regulus Therapeutics Inc's reporting currency: US Dollar USD
62.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 30 Jun 2024 | 12.85m | 19.63% |
| RA Capital Management LPas of 30 Jun 2024 | 6.25m | 9.55% |
| Octagon Capital Advisors LPas of 30 Sep 2024 | 4.26m | 6.51% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.09m | 6.25% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.63m | 5.55% |
| Deep Track Capital LPas of 30 Jun 2024 | 3.26m | 4.98% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.02m | 3.09% |
| Adage Capital Management LPas of 30 Jun 2024 | 2.00m | 3.06% |
| Opaleye Management, Inc.as of 30 Jun 2024 | 1.48m | 2.25% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.33m | 2.04% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
